1474034-05-3

Basic information

• Product Name: Nrf1-activator-1
• Synonyms: Nrf1-activator-1;RTA-408;Omaveloxolone (RTA-408);Omaveloxolone;N-(2-Cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide
• CAS NO: 1474034-05-3
• Molecular Formula: C33H44F2N2O3
• Molecular Weight: 554.7108664
• Mol File: 1474034-05-3.mol

Chemical Properties

• Boiling Point: 662.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Solubility: ≥55.5 mg/mL in DMSO; insoluble in H2O; ≥25.05 mg/mL in EtOH
• PKA: 13.71±0.70(Predicted)
• CAS DataBase Reference: Nrf1-activator-1(CAS DataBase Reference)
• NIST Chemistry Reference: Nrf1-activator-1(1474034-05-3)
• EPA Substance Registry System: Nrf1-activator-1(1474034-05-3)

Safety Data

• Hazardous Substances Data: 1474034-05-3(Hazardous Substances Data)

Usage

Uses

Used in Anticancer Applications:
Nrf1-activator-1 is used as an anticancer agent for its ability to inhibit tumor cell growth and metastasis. It targets oncogenic signaling pathways, making it a promising candidate for the treatment of various types of cancer. Additionally, it has been shown to protect human retinal pigment epithelial cells against H2O2-induced cell injury by activating NF-E2-related factor 2 (Nrf2), which plays a crucial role in the cellular antioxidant response.
Used in Anti-inflammatory Applications:
Nrf1-activator-1 is used as an anti-inflammatory agent due to its ability to modulate inflammation-related signaling pathways. By inhibiting the activation of these pathways, it can help reduce inflammation and its associated negative effects on the body.
Used in Antioxidant Applications:
Nrf1-activator-1 is used as an antioxidant agent to protect cells from oxidative stress and damage. Its activation of Nrf2 leads to the upregulation of antioxidant enzymes, which can help neutralize harmful reactive oxygen species (ROS) and prevent cellular damage.
Used in Pharmaceutical Industry:
Nrf1-activator-1 is used as a pharmaceutical candidate for its potential applications in the development of novel therapeutics targeting cancer, inflammation, and oxidative stress. Its multifaceted properties make it an attractive candidate for the creation of new drugs and treatment strategies.

Biological Activity

omaveloxolone (rta-408) is a novel synthetic triterpenoid that binds to kelch-like ech-associated protein 1 (keap1) and attenuate nuclear factor erythroid 2-related factor 2 (nrf2) degradation [1].keap1 is involved in proteasomal degradation of nrf2, thereby maintaining low basal levels of nrf2. binding to keap1 and blocking its ability to promote nrf2 degradation increase newly synthesized nrf2 accumulated in the nucleus where nrf2 increases the expression of antioxidant genes and decreases the expression of pro-inflammatory genes [1].in interferon-γ-stimulated raw 264.7 macrophage cells, low concentrations (≤ 25 nm) of rta-408 activated nrf2 and lowered nitric oxide and pro-inflammatory cytokine levels. at higher concentrations, rta-408 inhibited tumor cell growth, with gi50 of 260 ± 74 nm. meanwhile, rta-408 increased caspase activity in tumor cell lines, but not in normal primary human cells.in mice with radiation-induced dermatitis, topical application of rta-408 (0.01%, 0.1% and 1.0%, q.d.) resulted in dose-dependent improvements in the appearance of skin, with 1.0% rta-408 markedly reducing epidermal and collagen thickening, preventing dermal necrosis, and completely alleviating skin ulcers [2].[1]. probst b l, trevino i, mccauley l, et al. rta 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. plos one, 2015, 10(4): e0122942.[2]. reisman s a, lee c y, meyer c j, et al. topical application of the synthetic triterpenoid rta 408 protects mice from radiation-induced dermatitis. radiation research, 2014, 181(5): 512-520.

Upstream product

• 373-96-6 2,2-difluoropropanoic acid 
• 1192123-13-9 (4aR,6aS,6bR,8aS,12aS,12bR,14bS)-8a-amino-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-2-carbonitrile 
• 218600-44-3 bardoxolone 

Relevant articles and documents

2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF

The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.

2.2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF

The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.